Allos Therapeutics, Inc. Appoints David M. Stout to Its Board of Directors

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative new drugs for the treatment of cancer, today announced the appointment of David M. Stout, former President, Pharmaceuticals at GlaxoSmithKline, to the Company’s Board of Directors.

Back to news